Logo Logo

Publications by Ernst, T.

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 4.

Journal article

Drube, J.; Albert, B.; Pfirrmann, M.; Ernst, T.; Hochhaus, A.; Böhmer, F.-D (2016): Protein-tyrosine phosphatases modulate therapy response in CML cells. In: Oncology Research and Treatment, Vol. 39: p. 53

Lange, T.; Ernst, T.; Gruber, F.; Maier, J.; Cross, M.; Müller, M. C.; Niederwieser, D. W.; Hochhaus, A.; Pfirrmann, Markus (2013): The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. In: Haematologica, Vol. 98, No. 5: pp. 714-717

Schwaab, J.; Schnittger, S.; Sotlar, K.; Walz, C.; Fabarius, A.; Pfirrmann, Markus; Kohlmann, A.; Grossmann, V.; Meggendorfer, M.; Horny, H. P.; Valent, P.; Jawhar, M.; Teichmann, M.; Metzgeroth, G.; Erben, P.; Ernst, T.; Hochhaus, A.; Haferlach, T.; Hofmann, W. K.; Cross, N. C.; Reiter, A. (2013): Comprehensive mutational profiling in advanced systemic mastocytosis. In: Blood, Vol. 122, No. 14: pp. 2460-2466

Ernst, T.; Gruber, F. X.; Pelz-Ackermann, O.; Maier, J.; Pfirrmann, Markus; Muller, M. C.; Mikkola, I.; Porkka, K.; Niederwieser, D. W.; Hochhaus, A.; Lange, T. (2009): A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib. In: Haematologica, Vol. 94, No. 9: pp. 1227-1235

This list was generated on Wed May 12 00:27:43 2021 CEST.